BIOTRONIK Blog Explore our latest insightful interviews and articles Image Blog Stories Filter and Search Filter by year - Any -20252024202320222021 Search 46 blog articles Image Blog Mindfulness Isn’t Just a Buzzword at BIOTRONIK With 2023 upon us, BIOTRONIK employees are no exception to the kind of motivated goal-setting we often see at this time of year. Whether it’s more sports, a more mindful approach to everyday life, or to quit smoking—it’s important to have as much support as possible. That’s why BIOTRONIK’s Health Program 2023 will work to empower employees to achieve their health-related goals. 2023’s edition places a special focus on improving mental health at work, alongside the company’s work to promote physical health. Image Blog What We Eat—Some Surprises About Our Food and Heart Health 2022 has been a surprising year at times when it comes to studies of what we eat and how it affects heart health. Although there have been numerous publications looking at this relationship this year—a few stood out to us, and they may have interesting implications for our diets. Image Blog Pandemic Sees Big Jump in Remote Monitoring Use, but Reimbursement Still a Barrier Image Blog Why We Support More Representative Trials in Cardiology Cardiovascular research has achieved a lot in the last few decades—but even today the cardiology community is discussing whether the field needs gender-specific guidelines for treating cardiovascular diseases. One of the biggest obstacles is one of the most common problems in scientific research—a simple lack of data. Image Blog Supporting Cardiac Device Patients in Getting MRI Scans—How Should Physicians Facilitate? More than ten years after BIOTRONIK received approval for its first ProMRI pacemaker, allowing the first cardiac device patients access to MRI scans, we still get many questions from patients about what documents they should bring to a scanning appointment—to ensure their radiologist doesn’t turn them away. Image Blog How Strong Data Protection Can Help Drive Digital Health Advancements It’s hard to think of information that feels more personal than data about our own health. Yet we’re generating and monitoring more health data now than ever before. Whether it’s specific technology designed to help manage certain medical conditions—such as BIOTRONIK’s Patient App or remote care with Home Monitoring—or the plethora of more general, consumer-grade wearables and health apps, there are more and more digital options to help manage patient health. Image Blog “I did not let it throw me off course” How a CLS Pacemaker Helps Cabaret Artist Wolfgang Koch Live Life to the Fullest Image Blog Remote Patient Monitoring With Alert Based Care Is the Future for Managing Cied Patients A contribution by David Hayes, MD, Chief Medical Officer at BIOTRONIK Inc. Image Blog 60 Years of Saving Lives – How the BIOTRONIK Mission Began This year is a special year for BIOTRONIK, one in which we mark sixty years of service in the healthcare community. Pagination Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Previous page ‹ Previous Next page Next › Subscribe for our News You must have JavaScript enabled to use this form. Title Select TitleMsMrMXDrProf First name Last name Role Please select your roleHealthcare ProfessionalPatient or RelativeJournalistOther Email Phone Country/Region - Select -AfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua & BarbudaArgentinaArmeniaArubaAscension IslandAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBosnia & HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBritish Virgin IslandsBruneiBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCanary IslandsCape VerdeCaribbean NetherlandsCayman IslandsCentral African RepublicCeuta & MelillaChadChileChinaChristmas IslandClipperton IslandCocos (Keeling) IslandsColombiaComorosCongo - BrazzavilleCongo - KinshasaCook IslandsCosta RicaCroatiaCubaCuraçaoCyprusCzechiaCôte d’IvoireDenmarkDiego GarciaDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatiniEthiopiaFalkland IslandsFaroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard & McDonald IslandsHondurasHong Kong SAR ChinaHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKosovoKuwaitKyrgyzstanLaosLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacao SAR ChinaMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmar (Burma)NamibiaNauruNepalNetherlandsNetherlands AntillesNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorthern Mariana IslandsNorth KoreaNorth MacedoniaNorwayOmanOutlying OceaniaPakistanPalauPalestinian TerritoriesPanamaPapua New GuineaParaguayPeruPhilippinesPitcairn IslandsPolandPortugalPuerto RicoQatarRomaniaRussiaRwandaRéunionSamoaSan MarinoSarkSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint MaartenSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia & South Sandwich IslandsSouth KoreaSouth SudanSpainSri LankaSt. BarthélemySt. HelenaSt. Kitts & NevisSt. LuciaSt. MartinSt. Pierre & MiquelonSt. Vincent & GrenadinesSudanSurinameSvalbard & Jan MayenSwedenSwitzerlandSyriaSão Tomé & PríncipeTaiwanTajikistanTanzaniaThailandTimor-LesteTogoTokelauTongaTrinidad & TobagoTristan da CunhaTunisiaTurkmenistanTurks & Caicos IslandsTuvaluTürkiyeU.S. Outlying IslandsU.S. Virgin IslandsUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVatican CityVenezuelaVietnamWallis & FutunaWestern SaharaYemenZambiaZimbabweÅland Islands Topic Please select a topicProductsPatientsHealthcare Professionals I prefer to be contacted by Phone Email Message *Fields are mandatory. Latest Press Releases Show all press releases Image February 27, 2025 BERLIN, Germany BIOTRONIK Driving the Future of Active Device Business BIOTRONIK Driving the Future of Active Device Business BIOTRONIK, a global leader in medical technology, and a pioneer in cardiovascular, endovascular, and neuromodulation solutions, today announced a strategic shift to strengthen its leadership in active implantable devices and digital healthcare. Leveraging future technologies, including artificial intelligence (AI), remote patient monitoring and connected healthcare platforms, BIOTRONIK is at the forefront of improving patient outcomes and optimizing clinical workflows. These innovations are designed to enhance the efficiency and accessibility of care, enabling healthcare providers with next Image BÜLACH, Switzerland Press Release Two-Year BIOPACT Randomized Controlled Trial (RCT) Analysis Demonstrates “Persistent Excellence” for Low-Profile Passeo-18 Lux DCB BIOTRONIK announced the presentation of two-year results from the investigator-initiated BIOPACT RCT by Principal Investigator Dr. Koen Deloose at the Paris Vascular Insights 2023 congress. The randomized controlled non-inferiority trial evaluated the safety and efficacy of the Passeo®-18 Lux® drug-coated balloon (DCB) catheter compared to the In.Pact Admiral DCB (Medtronic), and showed excellent results for both balloons through 24 months. 1 The prospective, multicenter, core-lab adjudicated non-inferiority trial enrolled 302 patients in Austria, Belgium, France and Switzerland with Image AMSTERDAM, The Netherlands Press Release 12-Month-Data of BIOFLOW-DAPT Study Show Positive Results for Orsiro Mission DES With Short DAPT BIOFLOW-DAPT one-year-data demonstrated non-inferiority and a good safety profile for the Orsiro ® Mission drug-eluting stent (DES) compared to Resolute Onyx DES (p<0.0001) in patients at high risk of bleeding receiving short dual antiplatelet therapy (DAPT). Prof. Marco Valgimigli presented the novel data in a late-breaking trial session at the European Society of Cardiology’s (ESC) Congress in Amsterdam. The results were published simultaneously in Circulation. BIOFLOW-DAPT is a prospective, multi-center, international, two-arm randomized controlled clinical study to assess the safety of one Press Contact Corporate Public Relations & Communications press@biotronik.com +49 (0) 30 68905 1414 Get in contact
Image Blog Mindfulness Isn’t Just a Buzzword at BIOTRONIK With 2023 upon us, BIOTRONIK employees are no exception to the kind of motivated goal-setting we often see at this time of year. Whether it’s more sports, a more mindful approach to everyday life, or to quit smoking—it’s important to have as much support as possible. That’s why BIOTRONIK’s Health Program 2023 will work to empower employees to achieve their health-related goals. 2023’s edition places a special focus on improving mental health at work, alongside the company’s work to promote physical health.
Image Blog Mindfulness Isn’t Just a Buzzword at BIOTRONIK With 2023 upon us, BIOTRONIK employees are no exception to the kind of motivated goal-setting we often see at this time of year. Whether it’s more sports, a more mindful approach to everyday life, or to quit smoking—it’s important to have as much support as possible. That’s why BIOTRONIK’s Health Program 2023 will work to empower employees to achieve their health-related goals. 2023’s edition places a special focus on improving mental health at work, alongside the company’s work to promote physical health.
Image Blog What We Eat—Some Surprises About Our Food and Heart Health 2022 has been a surprising year at times when it comes to studies of what we eat and how it affects heart health. Although there have been numerous publications looking at this relationship this year—a few stood out to us, and they may have interesting implications for our diets.
Image Blog What We Eat—Some Surprises About Our Food and Heart Health 2022 has been a surprising year at times when it comes to studies of what we eat and how it affects heart health. Although there have been numerous publications looking at this relationship this year—a few stood out to us, and they may have interesting implications for our diets.
Image Blog Why We Support More Representative Trials in Cardiology Cardiovascular research has achieved a lot in the last few decades—but even today the cardiology community is discussing whether the field needs gender-specific guidelines for treating cardiovascular diseases. One of the biggest obstacles is one of the most common problems in scientific research—a simple lack of data.
Image Blog Why We Support More Representative Trials in Cardiology Cardiovascular research has achieved a lot in the last few decades—but even today the cardiology community is discussing whether the field needs gender-specific guidelines for treating cardiovascular diseases. One of the biggest obstacles is one of the most common problems in scientific research—a simple lack of data.
Image Blog Supporting Cardiac Device Patients in Getting MRI Scans—How Should Physicians Facilitate? More than ten years after BIOTRONIK received approval for its first ProMRI pacemaker, allowing the first cardiac device patients access to MRI scans, we still get many questions from patients about what documents they should bring to a scanning appointment—to ensure their radiologist doesn’t turn them away.
Image Blog Supporting Cardiac Device Patients in Getting MRI Scans—How Should Physicians Facilitate? More than ten years after BIOTRONIK received approval for its first ProMRI pacemaker, allowing the first cardiac device patients access to MRI scans, we still get many questions from patients about what documents they should bring to a scanning appointment—to ensure their radiologist doesn’t turn them away.
Image Blog How Strong Data Protection Can Help Drive Digital Health Advancements It’s hard to think of information that feels more personal than data about our own health. Yet we’re generating and monitoring more health data now than ever before. Whether it’s specific technology designed to help manage certain medical conditions—such as BIOTRONIK’s Patient App or remote care with Home Monitoring—or the plethora of more general, consumer-grade wearables and health apps, there are more and more digital options to help manage patient health.
Image Blog How Strong Data Protection Can Help Drive Digital Health Advancements It’s hard to think of information that feels more personal than data about our own health. Yet we’re generating and monitoring more health data now than ever before. Whether it’s specific technology designed to help manage certain medical conditions—such as BIOTRONIK’s Patient App or remote care with Home Monitoring—or the plethora of more general, consumer-grade wearables and health apps, there are more and more digital options to help manage patient health.
Image Blog “I did not let it throw me off course” How a CLS Pacemaker Helps Cabaret Artist Wolfgang Koch Live Life to the Fullest
Image Blog “I did not let it throw me off course” How a CLS Pacemaker Helps Cabaret Artist Wolfgang Koch Live Life to the Fullest
Image Blog Remote Patient Monitoring With Alert Based Care Is the Future for Managing Cied Patients A contribution by David Hayes, MD, Chief Medical Officer at BIOTRONIK Inc.
Image Blog Remote Patient Monitoring With Alert Based Care Is the Future for Managing Cied Patients A contribution by David Hayes, MD, Chief Medical Officer at BIOTRONIK Inc.
Image Blog 60 Years of Saving Lives – How the BIOTRONIK Mission Began This year is a special year for BIOTRONIK, one in which we mark sixty years of service in the healthcare community.
Image Blog 60 Years of Saving Lives – How the BIOTRONIK Mission Began This year is a special year for BIOTRONIK, one in which we mark sixty years of service in the healthcare community.
Image February 27, 2025 BERLIN, Germany BIOTRONIK Driving the Future of Active Device Business BIOTRONIK Driving the Future of Active Device Business BIOTRONIK, a global leader in medical technology, and a pioneer in cardiovascular, endovascular, and neuromodulation solutions, today announced a strategic shift to strengthen its leadership in active implantable devices and digital healthcare. Leveraging future technologies, including artificial intelligence (AI), remote patient monitoring and connected healthcare platforms, BIOTRONIK is at the forefront of improving patient outcomes and optimizing clinical workflows. These innovations are designed to enhance the efficiency and accessibility of care, enabling healthcare providers with next
Image February 27, 2025 BERLIN, Germany BIOTRONIK Driving the Future of Active Device Business BIOTRONIK Driving the Future of Active Device Business BIOTRONIK, a global leader in medical technology, and a pioneer in cardiovascular, endovascular, and neuromodulation solutions, today announced a strategic shift to strengthen its leadership in active implantable devices and digital healthcare. Leveraging future technologies, including artificial intelligence (AI), remote patient monitoring and connected healthcare platforms, BIOTRONIK is at the forefront of improving patient outcomes and optimizing clinical workflows. These innovations are designed to enhance the efficiency and accessibility of care, enabling healthcare providers with next
Image BÜLACH, Switzerland Press Release Two-Year BIOPACT Randomized Controlled Trial (RCT) Analysis Demonstrates “Persistent Excellence” for Low-Profile Passeo-18 Lux DCB BIOTRONIK announced the presentation of two-year results from the investigator-initiated BIOPACT RCT by Principal Investigator Dr. Koen Deloose at the Paris Vascular Insights 2023 congress. The randomized controlled non-inferiority trial evaluated the safety and efficacy of the Passeo®-18 Lux® drug-coated balloon (DCB) catheter compared to the In.Pact Admiral DCB (Medtronic), and showed excellent results for both balloons through 24 months. 1 The prospective, multicenter, core-lab adjudicated non-inferiority trial enrolled 302 patients in Austria, Belgium, France and Switzerland with
Image BÜLACH, Switzerland Press Release Two-Year BIOPACT Randomized Controlled Trial (RCT) Analysis Demonstrates “Persistent Excellence” for Low-Profile Passeo-18 Lux DCB BIOTRONIK announced the presentation of two-year results from the investigator-initiated BIOPACT RCT by Principal Investigator Dr. Koen Deloose at the Paris Vascular Insights 2023 congress. The randomized controlled non-inferiority trial evaluated the safety and efficacy of the Passeo®-18 Lux® drug-coated balloon (DCB) catheter compared to the In.Pact Admiral DCB (Medtronic), and showed excellent results for both balloons through 24 months. 1 The prospective, multicenter, core-lab adjudicated non-inferiority trial enrolled 302 patients in Austria, Belgium, France and Switzerland with
Image AMSTERDAM, The Netherlands Press Release 12-Month-Data of BIOFLOW-DAPT Study Show Positive Results for Orsiro Mission DES With Short DAPT BIOFLOW-DAPT one-year-data demonstrated non-inferiority and a good safety profile for the Orsiro ® Mission drug-eluting stent (DES) compared to Resolute Onyx DES (p<0.0001) in patients at high risk of bleeding receiving short dual antiplatelet therapy (DAPT). Prof. Marco Valgimigli presented the novel data in a late-breaking trial session at the European Society of Cardiology’s (ESC) Congress in Amsterdam. The results were published simultaneously in Circulation. BIOFLOW-DAPT is a prospective, multi-center, international, two-arm randomized controlled clinical study to assess the safety of one
Image AMSTERDAM, The Netherlands Press Release 12-Month-Data of BIOFLOW-DAPT Study Show Positive Results for Orsiro Mission DES With Short DAPT BIOFLOW-DAPT one-year-data demonstrated non-inferiority and a good safety profile for the Orsiro ® Mission drug-eluting stent (DES) compared to Resolute Onyx DES (p<0.0001) in patients at high risk of bleeding receiving short dual antiplatelet therapy (DAPT). Prof. Marco Valgimigli presented the novel data in a late-breaking trial session at the European Society of Cardiology’s (ESC) Congress in Amsterdam. The results were published simultaneously in Circulation. BIOFLOW-DAPT is a prospective, multi-center, international, two-arm randomized controlled clinical study to assess the safety of one